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Background. Antiretroviral therapy (ART) was highly efﬁcacious in preventing human immunodeﬁciency virus (HIV) trans-
mission in stable serodiscordant couples in the HPTN-052 study, a resource-intensive randomized controlled trial with near-perfect
ART adherence and mutual HIV status disclosure among all participating couples. However, minimal evidence exists of the effec-
tiveness of ART in preventing HIV acquisition in stable serodiscordant couples in “real-life” population-based settings in hyperen-
demic communities of sub-Saharan Africa, where health systems are typically resource-poor and overburdened, adherence to ART is
often low, and partners commonly do not disclose their HIV status to each other.
Methods. Data arose from a population-based open cohort in KwaZulu-Natal, South Africa. A total of 17 016 HIV-uninfected
individuals present between January 2005 and December 2013 were included. Interval-censored time-updated proportional hazards
regression was used to assess how the ART status affected HIV transmission risk in stable serodiscordant relationships.
Results. We observed 1619 HIV seroconversions in 17 016 individuals, over 60 349 person-years follow-up time. During the
follow-up period, 1846 individuals had an HIV-uninfected and 196 had an HIV-infected stable partner HIV incidence was 3.8/
100 person-years (PY) among individuals with an HIV-infected partner (95% conﬁdence interval [CI], 2.3–5.6), 1.4/100 PY (.4–
3.5) among those with HIV-infected partners receiving ART, and 5.6/100 PY (3.5–8.4) among those with HIV-infected partners
not receiving ART. Use of ART was associated with a 77% decrease in HIV acquisition risk among serodiscordant couples (adjusted
hazard ratio, 0.23; 95% CI, .07–.80).
Conclusions. ART initiation was associated with a very large reduction in HIV acquisition in serodiscordant couples in rural
KwaZulu-Natal. However, this “real-life” effect was substantially lower than the effect observed in the HPTN-052 trial. To eliminate
HIV transmission in serodiscordant couples, additional prevention interventions are probably needed.
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Human immunodeﬁciency virus (HIV) transmission within sta-
ble heterosexual partnerships is thought to be a major contribu-
tor to new HIV infection in sub-Saharan Africa (SSA) [1–3]. In
the era before antiretroviral therapy (ART), HIV incidence was
estimated at approximately 5 cases per 100 person-years (PY)
among men and 10/100 PY among women in serodiscordant
relationships in Tanzania [4] and Uganda [2]. Higher HIV
incidence among women in serodiscordant relationships may
be related to higher per-act probability of HIV transmission
among women than among men [5]. In some studies from
SSA, marriage has been implicated as a risk factor for HIV acqui-
sition among women [6, 7], perhaps owing to greater vulnerabil-
ity to HIV within marriage (eg, due to difﬁculty negotiating
condom use) [8–11].
The introduction of ART has resulted in dramatic decreases
in HIV transmission globally [12–16]. The landmark HPTN-
052 study demonstrated that immediate ART initiation can
nearly eliminate ART transmission in serodiscordant couples
[12]. A recent meta-analysis showed greatly reduced HIV trans-
mission in serodiscordant couples in whom the HIV-infected
partner is virally suppressed [13]. Increasing ART coverage at
the community [14] and household [16] level is associated
with decreased HIV transmission, and modeling studies have
suggested that HIV transmission could be eliminated at 90%
ART coverage [17].However, estimates of the ART effect in pre-
venting HIV transmission has primarily arisen from clinical
randomized trials and clinical cohort studies. Participants in
Received 1 April 2016; accepted 7 May 2016; published online 20 May 2016.
Correspondence: T. Bärnighausen, Africa Centre for Population Health, PO Box 198, 3935 Mtu-
batuba, South Africa (tbarnighausen@africacentre.ac.za).
Clinical Infectious Diseases® 2016;63(4):548–54
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of
America. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly
cited. DOI: 10.1093/cid/ciw335
548 • CID 2016:63 (15 August) • HIV/AIDS
these studies were enrolled through either serodiscordant couple
clinics or partner testing programs. These studies were highly con-
trolled and resource-intensive and thus do not represent the “real-
life” settings of resource-poor public-sector health systems in the
hyperendemic communities of SSA. For instance, in HPTN-052
viral suppression was >89% among individuals immediately initi-
ating ART [18]; in contrast, in public-sector ART clinics in Kwa-
Zulu-Natal viral load suppression was 77% [19]. Such differences
in viral load suppression are likely to lead to differential effective-
ness of ART in preventing HIV transmission. Importantly, all in-
dividuals in the prior studies were aware of their HIV status and
had disclosed their status to their partners [20–25]. In “real-life”
settings in SSA, individuals commonly do not disclose their HIV
status to their partners for fear of negative consequences to their
lives [26].
To date, no empirical estimates exist of the effect of ART on
HIV transmission in “real-life” populations of serodiscordant
couples and in settings with resource-poor health systems. In
this study, we aim to establish such evidence in an HIV hyper-
endemic rural community in KwaZulu-Natal.
METHODS
Study Setting
Data arose from the population-based longitudinal surveillance
program conducted by the Africa Centre for Population Health
(hereafter, “Africa Centre”) [27]. This surveillance program is
located in a predominantly rural community of uMkhanyakude
district in the province of KwaZulu-Natal. The Africa Centre
has conducted an HIV surveillance program since 2003, includ-
ing conﬁdential HIV testing, collection of sexual history and be-
haviors, relationship status, and household demographic data.
The surveillance includes all members of all households located
in the 438-km2 demographic surveillance area.
KwaZulu-Natal is the province that bears the largest HIV
burden in South Africa [28–30]. Age-speciﬁc incidence peaks
at >6/100 PY among women in KwaZulu-Natal and 4/100 PY
among men [14, 31, 32]. Adult HIV prevalence in this region
is 29% [33], and only 34% of working-age adults are employed
[34]. ART coverage has increased rapidly since 2004, primarily
via nurse-led public sector ART programs [14, 33], but rates of
viral suppression and immunologic recovery among ART pa-
tients are comparatively low [19]. ART is provided primarily
in primary care clinics run by nurses [19]. Although ART cov-
erage has expanded rapidly [14], the program suffers from more
drug stockouts, and greater difﬁculty with retention in care,
leading to lower viral suppression compared to HPTN-052
[18, 19].
Participants and Procedures
Data were available from January 2005 through December 2013.
Participants were included in this analysis if they had a ﬁrst neg-
ative HIV test result followed by ≥1 subsequent HIV test
(regardless of result) and, for those in stable relationships, re-
ported only a single stable partner. Baseline was considered
the earliest date at which an individual tested HIV negative.
Ethical approval for data collection, linkage, and analysis was
obtained from the University of KwaZulu-Natal Biomedical Re-
search Ethics Committee, and written informed consent was
obtained from all participants. The analyses presented here
used only secondary and anonymized data and were thus ex-
empted from additional ethical review by the Institutional Re-
view Board.
Outcome Ascertainment
The primary outcome for analyses was the time to HIV sero-
conversion, where seroconversion required ≥1 negative HIV
test results followed by ≥1 positive result.
Exposure Ascertainment
The primary exposures of interest were the HIV and ART status
of each respondent’s partner. In this region, a large number of
individuals are in primary, cohabiting, “conjugal relationships”
(henceforth, “stable partnerships”), in which they are members
of the same household, may have had children together, and are
socially recognized as partners [35]. These partnerships are
more common among older than among younger individuals,
who more frequently live in households headed by their parents
or kin. Stable partnerships were identiﬁed via demographic
household surveillance data. Unique Africa Centre identiﬁca-
tion codes were used to link partners to one another. Stable
partnerships remain under observation until they are reported
to have ended by either partner during a household visit.
The HIV status of each stable partner was ascertained from
HIV surveillance data. Respondents were considered to be in a
serodiscordant relationship if their stable partner had tested
positive before or at the same time as the respondent’s current
negative HIV test, or if the partner had initiated ART before the
respondent’s current test. Respondents were considered to be in
a seroconcordant HIV negative relationship if their partner test-
ed HIV negative on or after the day the respondent him or her-
self tested negative. Respondents were censored at the end of the
relationship, on the date of their ﬁrst positive HIV test result, or
on the date of their last negative HIV test result, whichever was
ﬁrst.
To determine the ART status of HIV-infected partners, we
linked demographic surveillance data to information from the
Hlabisa HIV Treatment and Care Programme, which provides
ART through 17 public-sector primary care clinics in the area
which includes the Africa Centre surveillance area. HIV-infected
partners were deﬁned as receiving ART at the time of a demo-
graphic surveillance visit if they had a record of having initiated
ART before that date.
Respondents not in stable partnerships were categorized as
being in another type of relationship or not, based on self-
reported relationship status. Participants who reported being
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married or engaged, but not, cohabiting with their partner, were
coded as being in a noncohabiting relationship. Those who did
not report a current relationship were coded as such. Partner-
ship, HIV, and ART status could vary over time and we thus
treated them as time-varying variables in our analyses. Individ-
uals could contribute person-time to multiple exposure
categories.
Covariates
Time-varying potential confounders included respondent-
reported current completed education (none or primary, 0–
7 years; secondary, 8–12 years; tertiary, >12 years), household
wealth (quintiles of the ﬁrst component identiﬁed by princi-
pal components analysis of 32 household assets and charac-
teristics), having had >1 partner in the past 12 months, and
inconsistent condom use with any partner in the past 12
months. Additional covariates included age at baseline and
sex.
Statistical Methods
Exact HIV seroconversion dates are not typically observed in
cohort study research. Instead, the event time is “interval cen-
sored,” in that it is known that it occurs within an interval of
time (between the dates of the last negative and the ﬁrst pos-
itive HIV test result). The standard approach to the use of in-
terval-censored data is to impute an exact seroconversion date,
for example, by assuming that the HIV seroconversion oc-
curred at the midpoint between the dates of the last negative
and the ﬁrst positive HIV test [36]. However, this approach
has been demonstrated to lead to underestimated standard er-
rors and can lead to misclassiﬁcation if the date of a time-
varying exposure is known with precision but not the event
date of HIV seroconversion [36]. Here, the date of exposure
is known with precision because ART initiation dates are ex-
tracted from clinical HIV treatment program data, while exact
HIV seroconversion dates are not known with precision owing
to the annual nature of the HIV surveillance. To avoid the
problems associated with exact seroconversion date imputa-
tion, we ﬁtted interval-censored parametric proportional
hazards models, which appropriately account for both uncer-
tainty regarding HIV seroconversion timing and the time-
varying nature of the exposure and potential confounders
[37, 38].
A series of 3 models were included for each contrast of inter-
est (HIV-infected vs HIV-uninfected partner; HIV-infected
partner receiving vs not receiving ART). Model 1 contained
an indicator term for each partnership status category, the indi-
vidual’s age, sex, and an indicator for year of observation. In
model 2 we added educational attainment and household
wealth as additional covariates. In model 3, we further added
sexual behavior variables. For models considering the effect of
partner HIV status on HIV incidence, the referent category was
having an HIV-uninfected partner. For models considering the
effect of partner ART status, the HIV-infected partner’s ART
status was modeled as the proportion of the interval that was
covered by ART. This indicator variable could thus range
from 0 to 1.
Several sensitivity analyses were performed. First, given that
ART use does not result in immediate viral suppression, we
modeled the partner’s ART use with a “wash-in” period of 30
days, assuming that the ﬁrst 30 days after ART initiation were
untreated in an interval-censored model. Second, we repeated
our analyses with a Cox proportional hazards model using a
midpoint imputed HIV seroconversion date, to compare the re-
sults based on the interval-censored approach to those based on
the more standard midpoint imputation approach. Analyses
were performed using SAS 9.2 (SAS Institute Inc, Cary, North
Carolina) and Stata 13.1 software (StataCorp, College Station,
Texas).
RESULTS
Between January 2005 and December 2013, 17 016 individuals
contributing 60 349 PY of follow up met the inclusion criteria.
Of 2029 individuals with a cohabiting partner during the fol-
low-up period, 196 individuals had an HIV-infected cohabiting
partner, and 1846 individuals had an HIV-uninfected stable
partner. Of individuals with an HIV-infected cohabiting part-
ner, 20 were receiving ART at baseline, and a further 56 started
ART during the follow-up period. Individuals were tested for
HIV between 2 and 9 times (24.4% were tested twice, 21.4% 3
times, 32.1% 4–5 times, 17.5% 6–7 times, and 4.6% 8 or 9
times). The median time between tests was 374 days (interquar-
tile range, 352–700 days). Table 1 lists baseline characteristics
Table 1. Baseline Descriptive Characteristics by Respondent Sex
Characteristic
Respondents, No. (%)a
All
(N = 17 016)
Male
(n = 6355)
Female
(n = 10 661)
Age at baseline, mean (SD), y 33.2 (20.5) 28.6 (17.9) 36.0 (20.5)
Educational attainment, %
None or primary (0–7 y) 40.8 36.8 43.2
Secondary (8–12 y) 55.3 59.0 53.0
Tertiary 3.9 4.3 3.7
Household wealth quintile, %
Lowest 19.7 19.0 20.1
2nd lowest 26.7 26.0 27.1
Middle 24.3 24.7 24.0
2nd highest 16.5 16.6 16.4
Highest 12.9 13.7 12.4
Multiple partners in past
12 mo, %
3.3 7.2 0.6
Any inconsistent condom use
in past 12 mo, %
37.4 29.1 42.9
Knows own HIV status, % 29.3 20.9 34.1
Abbreviations: HIV, human immunodeficiency virus; SD, standard deviation.
a Data represent % of respondents unless otherwise specified.
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for the study sample. Approximately 63% of the study sample
was female, and women tended to be older than men (mean
age, 36 vs 29 years, respectively). At baseline, 29% of partici-
pants reported being aware of their HIV status.
Table 2 shows HIV incidence by partnership status. We ob-
served 1619 HIV seroconversions in 17 106 individuals over 60
349 person-years follow-up time and the overall HIV incidence
was 2.7 new infections per 100 PY (95% conﬁdence interval
[CI], 2.6–2.8/100 PY). HIV incidence was 5.6/100 PY (95%
CI, 3.5–8.4/100 PY) among individuals with an HIV-infected
partner not receiving ART, 1.4/100 PY (.4–3.5/100 PY)
among those with an HIV-infected partner receiving ART,
and 0.3/100 PY (.2–.5/100 PY) among those with an HIV-
uninfected partner. Men with HIV-uninfected partners had a
higher HIV incidence than women with HIV-uninfected part-
ners, whereas women with HIV-infected partners had higher
HIV incidence than men with HIV-infected partners.
All partnership categories had signiﬁcantly elevated HIV
incidence compared with individuals in stable partnerships
with HIV-uninfected partners (Table 3). Individuals with an
HIV-infected stable partner had the greatest elevation in HIV
incidence, with incidence >10 times that of individuals with
Table 2. Human Immunodeficiency Virus Incidence by Partner Status and Sex
Partner Status
Overall Women Men
HIV
Seroconversions,
No. PY
Incidence Rate,
Seroconversions/
100 PY
HIV
Seroconversions,
No. PY
Incidence Rate,
Seroconversions/
100 PY
HIV
Seroconversions,
No. PY
Incidence Rate,
Seroconversions/
100 PY
HIV uninfected 20 6644 0.3 (.2–.5) 8 3720 0.2 (.1–.4) 12 2923 0.4 (.2–.7)
HIV infected 27 707 3.8 (2.3–5.6) 20 406 4.9 (3.0–7.6) 7 302 2.3 (.9–4.8)
Receiving ART 4 294 1.4 (.4–3.5) 4 179 2.2 (.6–5.7) 0 116 0 (0–3.2)
Not receiving ART 23 413 5.6 (3.5–8.4) 16 227 7.0 (4.0–11.4) 7 186 3.8 (1.5–7.8)
Unknown partner
status
197 10 713 1.8 (1.6–2.1) 148 8492 1.7 (1.5–2.0) 49 2221 2.2 (1.6–2.9)
In a noncohabiting
relationship
78 2171 3.6 (2.8–4.5) 64 1632 3.9 (3.0–5.0) 14 538 2.6 (1.4–4.4)
Not in a relationship 1297 40 114 3.2 (3.1–3.4) 1003 25 335 4.0 (3.7–4.2) 294 14 779 2.0 (1.8–2.2)
Overall 1619 60 349 2.7 (2.6–2.8) 1243 39 586 3.1 (3.0–3.3) 376 20 763 1.8 (1.6–2.0)
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; PY, person-years.
Table 3. Association Between Partner Serostatus and Human Immunodeficiency Virus Acquisition
Characteristic
Model 1a Model 2a Model 3a
AHR (95% CI) P Value AHR (95% CI) P Value AHR (95% CI) P Value
HIV-uninfected partner 1.00 . . . 1.00 . . . 1.00 . . .
HIV-infected partner 9.91 (5.48–17.94) <.001 9.71 (5.36–17.60) <.001 10.04 (5.51–18.32) <.001
Unknown partner status 4.26 (2.63–6.89) <.001 4.26 (2.63–6.90) <.001 4.36 (2.67–7.13) <.001
In a noncohabiting relationship 6.61 (3.94–11.06) <.001 6.63 (3.95–11.10) <.001 6.26 (3.71–10.58) <.001
Not in a relationship 5.98 (3.73–9.60) <.001 6.02 (3.75–9.66) <.001 6.42 (3.97–10.40) <.001
Female sex 2.19 (1.94–2.46) <.001 2.18 (1.93–2.45) <.001 2.24 (1.98–2.54) <.001
Age at baseline 1.13 (1.10–1.16) <.001 1.13 (1.10–1.16) <.001 1.11 (1.08–1.12) <.001
Age squared 0.998 (.997 to.998) <.001 0.998 (.997 to.998) <.001 0.998 (.997 to.999) <.001
Educational attainment
None or primary (0–7 y) . . . . . . 1.00 . . . 1.00 . . .
Secondary (8–12 y) . . . . . . 0.99 (.86–1.13) .85 0.93 (0.81–1.07) .31
Tertiary . . . . . . 0.94 (.73–1.22) .66 0.88 (.67–1.14) .33
Household wealth quintile
Lowest . . . . . . 1.00 . . . 1.00 . . .
2nd lowest . . . . . . 1.20 (1.02–1.41) .03 1.17 (.99–1.37) .07
Middle . . . . . . 1.28 (1.09–1.41) .002 1.28 (1.09–1.50) .003
2nd highest . . . . . . 1.24 (1.06–1.46) .008 1.24 (1.05–1.46) .01
Highest . . . . . . 1.06 (.89–1.26) .54 1.08 (.90–1.28) .41
Multiple partners in past 12 mo . . . . . . . . . . . . 2.25 (1.76–2.88) <.001
Any inconsistent condom use in past 12 mo . . . . . . . . . . . . 1.72 (1.56–1.92) <.001
Abbreviations: AHR, adjusted hazard ratio; CI, confidence interval; HIV, human immunodeficiency virus.
a The 3 models are described in “Statistical Methods” section.
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HIV-uninfected stable partners (adjusted hazard ratio, 10.04;
95% CI, 5.51–18.32; Table 3). This result was robust to adjust-
ment for factors related to socioeconomic status and sexual
behavior (Table 3). The use of ART by an HIV-infected partner
was associated with a 77% reduction in HIV incidence com-
pared with no ART use by an HIV-infected partner (adjusted
hazard ratio, 0.23; 95% CI, .07–.80; Table 4 and Figure 1). As
expected, this effect was slightly stronger than that estimated
by the midpoint imputed Cox proportional hazards model
(adjusted hazard ratio, 0.28; 95% CI, .10–.80; Supplementary
Table 4), with a slightly wider CI. Our results were robust to
assuming no effect of ART during the ﬁrst 30 days after ART
initiation (Supplementary Table 5).
DISCUSSION
In controlled and resource-intensive randomized trials and clin-
ical cohort studies, early initiation of ART dramatically reduces
HIV transmission to uninfected partners in serodiscordant
relationships [12, 15, 39]. In the landmark HPTN-052
study, immediate ART initiation resulted in a 96% reduction
in linked HIV transmission and 89% reduction in overall
HIV transmission among serodiscordant couples [12]. In the
present study, we estimated the effect of ART in reducing
HIV acquisition in serodiscordant couples in a “real-life” pop-
ulation-based setting. We found that ART is highly effective in
reducing HIV acquisition in serodiscordant couples in a poor
HIV-hyperendemic community, despite severe resource con-
straints in the public-sector health system in this setting.
In this community, ART is delivered through primary care
clinics that are staffed and led exclusively by nurses. Supply
chain failures in this setting have frequently led to drug stockouts
during the observation period, patients commonly miss sched-
uled visits to the ART program, and adherence to ART is lower
than in more tightly controlled study settings. Despite these im-
perfections of “real-life” ART delivery, our results demonstrate
that ART is highly effective in preventing HIV transmission in
serodiscordant couples. Because this study was population-
based, including all stable discordant couples in the community,
our ﬁndings are generalizable beyond those of the previous con-
trolled clinical studies, which enrolled only individuals who,
ﬁrstly, used healthcare targeting couples and, secondly, had dis-
closed their HIV status to their partners [12, 20–24, 40].
Our results must be considered in the context of several lim-
itations. First, as with any long-term population-based study,
there was some attrition and nonresponse. Selection bias
could be introduced if those who tested systematically differed
from those who declined testing. Second, we cannot rule out
bias due to unmeasured confounding. For example, individuals
with greater general engagement with health services may be
both more likely to initiate ART and more likely to use con-
doms. However, the longitudinal nature of this analysis allowed
for adjustment of time-varying confounding by a range of
Table 4. Association Between Partner Antiretroviral Therapy Status and Human Immunodeficiency Virus Acquisition
Characteristic
Model 1a Model 2a Model 3a
AHR (95% CI) P Value AHR (95% CI) P Value AHR (95% CI) P Value
HIV-infected partner, not receiving ART 1.00 . . . 1.00 . . . 1.00 . . .
HIV-infected partner, receiving ART 0.23 (.07–.80) .02 0.23 (.07–.80) .02 0.23 (.07–.80) .02
HIV-uninfected partner 0.08 (.05–.15) <.001 0.09 (.05–.16) <.001 0.08 (.04–.15) <.001
Unknown partner status 0.32 (.21–.50) <.001 0.33 (.21–.51) <.001 0.32 (0.21–.50) <.001
In a noncohabiting relationship 0.50 (.31–.80) .004 0.51 (.32–.82) .005 0.46 (.29–.73) .001
Not in a relationship 0.46 (.30–.70) .0003 0.46 (.30–.70) .0004 0.47 (.31–.72) .0005
Female sex (No., %) 2.19 (1.95–2.46) <.001 2.18 (1.94–2.45) <.001 2.25 (1.99–2.54) <.001
Age at baseline 1.13 (1.10–1.16) <.001 1.13 (1.10–1.16) <.001 1.11 (1.08–1.14) <.001
Age squared 0.998 (.997–.998) <.001 0.998 (.997–.998) <.001 0.998 (.997–.998) <.001
Educational attainment
None or primary (0–7 y) . . . . . . 1.00 . . . 1.00 . . .
Secondary (8–12 y) . . . . . . 0.99 (.86–1.13) .84 0.93 (.81–1.07) .33
Tertiary . . . . . . 0.94 (.72–1.22) .62 0.89 (.68–1.15) .37
Household wealth quintile
Lowest . . . . . . 1.00 . . . 1.00 . . .
2nd lowest . . . . . . 1.20 (1.02–1.41) .03 1.17 (.99–1.38) .06
Middle . . . . . . 1.28 (1.09–1.51) .003 1.28 (1.09–1.51) .003
2nd highest . . . . . . 1.24 (1.06–1.46) .008 1.24 (1.05–1.45) .01
Highest . . . . . . 1.06 (.89–1.26) .53 1.07 (.90–1.27) .43
Multiple partners in past 12 mo . . . . . . . . . . . . 2.26 (1.76–2.89) <.001
Any inconsistent condom use in past 12 mo . . . . . . . . . . . . 1.73 (1.56–1.92) <.001
Abbreviations: AHR, adjusted hazard ratio; ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus.
a The 3 models are described in “Statistical Methods” section.
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sociodemographic and behavioral factors that probably at least
partially control for such effects. Importantly, the large effect
sizes in this study mean that any bias due to confounding
would have to be considerable to nullify these results.
Third, although this study represents a true population cohort,
our ﬁndings may not be generalizable to all contexts. In rural
South Africa, cohabitation and conjugal relationships tend to
occur at older ages [35],whereas HIV incidence is highest in youn-
ger men and women [14, 29]. Sexual partnership structures sim-
ilar to those observed in our study population are also found in
other poor rural settings in Southern Africa. However, our results
may not be generalizable to communities with different partner-
ships structures, for example, where serodiscordant partnerships
are prevalent among younger individuals. Finally, the observed
HIV incidence among individuals with HIV-uninfected stable
partners was relatively low, and although this may partially reﬂect
overall lower HIV risk behaviors among this population, it may
also reﬂect a selection effect: in this setting of very high HIV prev-
alence, those who have not already acquired HIV by the time they
enter a stable partnership may have lifelong risk behaviors that are
qualitatively different from the rest of the population.
In conclusion, ART is a highly effective strategy to prevent
HIV transmission in serodiscordant couples, even when it is pro-
vided to a population with low levels of HIV status disclosure and
through a resource-poor, public-sector healthcare system in a hy-
perendemic community. Although the HIV prevention effect of
ART in this “real-life” setting is large, it falls short of the near-
complete elimination of HIV transmission observed in the
HPTN-052 study, suggesting that additional prevention interven-
tions will probably be required to eliminate HIV transmission in
serodiscordant couples in SSA.
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